Works by Larsen, Jeremy
Results: 24
Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
- By:
- Publication type:
- Article
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00794-x
- By:
- Publication type:
- Article
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00752-z
- By:
- Publication type:
- Article
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 5, p. 1, doi. 10.1038/s41408-020-0320-7
- By:
- Publication type:
- Article
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 6, p. 456, doi. 10.1016/j.clml.2023.03.002
- By:
- Publication type:
- Article
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
- By:
- Publication type:
- Article
IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S401, doi. 10.1016/S2152-2650(21)01906-6
- By:
- Publication type:
- Article
Poster: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01536-6
- By:
- Publication type:
- Article
Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01277-5
- By:
- Publication type:
- Article
A Phase 1b/2a Study of the CELMoD Iberdomide (CC-220) in Combination With Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e52, doi. 10.1016/j.clml.2019.09.080
- By:
- Publication type:
- Article
Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies.
- Published in:
- Oncology & Therapy, 2015, v. 3, n. 1/2, p. 47, doi. 10.1007/s40487-015-0009-4
- By:
- Publication type:
- Article
Impact of belantamab mafodotin‐induced ocular toxicity on outcomes of patients with advanced multiple myeloma.
- Published in:
- British Journal of Haematology, 2022, v. 199, n. 1, p. 95, doi. 10.1111/bjh.18298
- By:
- Publication type:
- Article
Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 8, p. 759, doi. 10.1002/ajh.24762
- By:
- Publication type:
- Article
Symptomatic Hypoalbuminemia as an Indication for Treatment of Waldenström Macroglobulinemia: A Case Report and Review of the Literature.
- Published in:
- Case Reports in Hematology, 2019, p. 1, doi. 10.1155/2019/1929124
- By:
- Publication type:
- Article
Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
- Published in:
- Leukemia & Lymphoma, 2024, v. 65, n. 12, p. 1789, doi. 10.1080/10428194.2024.2373331
- By:
- Publication type:
- Article
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
- Published in:
- Leukemia & Lymphoma, 2013, v. 54, n. 8, p. 1713, doi. 10.3109/10428194.2012.753444
- By:
- Publication type:
- Article
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 1, p. 49, doi. 10.1002/ajh.26762
- By:
- Publication type:
- Article
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 5, p. 630, doi. 10.1002/ajh.26498
- By:
- Publication type:
- Article
Assessment of fixed‐duration therapies for treatment‐naïve Waldenström macroglobulinemia.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 945, doi. 10.1002/ajh.26210
- By:
- Publication type:
- Article
Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
- Published in:
- Current Hematologic Malignancy Reports, 2016, v. 11, n. 2, p. 127, doi. 10.1007/s11899-016-0310-9
- By:
- Publication type:
- Article